TD Waterhouse Canada Inc. Has $2.77 Million Stock Holdings in IQVIA Holdings Inc. $IQV

Posted by Stanley Muller on Sep 8th, 2026

TD Waterhouse Canada Inc. increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 79.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 13,640 shares of the medical research company’s stock after acquiring an additional 6,033 shares during the period. TD Waterhouse Canada Inc.’s holdings in IQVIA were worth $2,772,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in IQV. Financial Freedom LLC acquired a new position in IQVIA during the first quarter worth approximately $25,000. Ascentis Independent Advisors acquired a new position in shares of IQVIA during the 1st quarter worth approximately $25,000. International Assets Investment Management LLC acquired a new position in shares of IQVIA during the 4th quarter worth approximately $27,000. Compass Financial Management LLC acquired a new stake in IQVIA during the 2nd quarter valued at $27,000. Finally, Gilpin Wealth Management LLC bought a new position in IQVIA during the fourth quarter worth $27,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

IQVIA stock opened at $267.34 on Tuesday. The stock’s fifty day moving average price is $232.02 and its two-hundred day moving average price is $193.57. The firm has a market cap of $44.00 billion, a PE ratio of 33.17, a price-to-earnings-growth ratio of 2.29 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $271.80.

IQVIA (NYSE:IQV – Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.IQVIA’s revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the business earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, research analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

Insider Transactions at IQVIA

In other news, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the transaction, the insider owned 1,348 shares in the company, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider James G. Berkshire sold 2,668 shares of IQVIA stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the sale, the insider directly owned 10,890 shares in the company, valued at $2,845,883.70. This trade represents a 19.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 15,581 shares of company stock worth $3,796,021. 1.70% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms have recently issued reports on IQV. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a research note on Thursday, July 9th. JPMorgan Chase & Co. upped their target price on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Morgan Stanley reissued an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Stifel Nicolaus upped their price objective on IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Finally, HSBC reissued a “buy” rating and set a $240.00 target price on shares of IQVIA in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $243.62.

Check Out Our Latest Stock Analysis on IQVIA

IQVIA Company Profile

(Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.